EGFR and paronychia: PCR-based EGFR mutation profiling revealed the tumor harbored the EGFRΔ19del mutation, leading to treatment with afatinib from August 2023 until March 2025, when therapy was discontinued due to grade I–II rash and grade III paronychia.